Featured article: Optimizing biologic treatment in inflammatory bowel disease

The advent of biologic agents for the treatment of inflammatory bowel disease (IBD) was accompanied in parallel with emerging understanding of persisting underlying inflammation and ensuing bowel damage that can occur even in patients with seeming clinical remission. Therefore, to optimize biologic treatments of IBD, we must understand how to practically monitor IBD patients, which objective measures to follow, at what time-points and whether to act upon results in asymptomatic patients. In this article, the authors provide an exhaustive review of objective measures available for monitoring of IBD patients, focusing on the challenging group of patients treated by biologic agents.

Read More

Articles

  1. Research article

    High prevalence of advanced colorectal neoplasia in the Thai population: a prospective screening colonoscopy of 1,404 cases

    Bunchorn Siripongpreeda, Chulabhorn Mahidol, Navara Dusitanond, Tassanee Sriprayoon, Bunlung Muyphuag, Thaniya Sricharunrat, Narongchai Teerayatanakul, Watanya Chaiwong, Wipra Worasawate, Prassanee Sattayarungsee, Juthamas Sangthongdee, Jirapa Prarom, Gaidganok Sornsamdang, Kamonwan Soonklang, Kasiruck Wittayasak and Chirayu U. Auewarakul

    Published on: 23 August 2016

View all articles

View all articles

Aims and scope

BMC Gastroenterology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of gastrointestinal and hepatobiliary disorders, as well as related molecular genetics, pathophysiology, and epidemiology.

Editor

  • Christopher Morrey, BioMed Central

Section Editors

  • Jan Bornschein, Otto-von-Guericke-University of Magdeburg
  • Peter Lakatos, Semmelweis University
  • Rakesh Tandon, Pushpawati Singhania Research Institute
  • Christian Trautwein, University Hospital Aachen
  • Arndt Vogel, Medical School Hannover


Tweets

Advertisement